首页 > 最新文献

Drug and Therapeutics Bulletin最新文献

英文 中文
Safety update: statins and myasthenia gravis. 安全更新:他汀类药物和重症肌无力。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2023-12-27 DOI: 10.1136/dtb.2023.000063

Overview of: Medicines and Healthcare products Regulatory Agency. Statins: very infrequent reports of myasthenia gravis.Drug Safety Update 2023;17(2):1.

概述：药品和保健品管理局。他汀类药物：关于肌无力的极少数报告.药物安全更新 2023；17（2）：1.
{"title":"Safety update: statins and myasthenia gravis.","authors":"","doi":"10.1136/dtb.2023.000063","DOIUrl":"10.1136/dtb.2023.000063","url":null,"abstract":"<p><p><b>Overview of:</b> Medicines and Healthcare products Regulatory Agency. Statins: very infrequent reports of myasthenia gravis.<i>Drug Safety Update</i> 2023;17(2):1.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138482158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SGLT2 inhibitor associated euglycaemic diabetic ketoacidosis in an orthopaedic trauma patient. 一名骨科创伤患者因服用 SGLT2 抑制剂而出现优生糖尿病酮症酸中毒。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2023-12-27 DOI: 10.1136/dtb.2023.250233rep
Duncan Taylor Ritchie, James Dixon
{"title":"SGLT2 inhibitor associated euglycaemic diabetic ketoacidosis in an orthopaedic trauma patient.","authors":"Duncan Taylor Ritchie, James Dixon","doi":"10.1136/dtb.2023.250233rep","DOIUrl":"10.1136/dtb.2023.250233rep","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"11-15"},"PeriodicalIF":0.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9748476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hydrocortisone for severe community acquired pneumonia in ICU. 氢化可的松治疗重症社区获得性肺炎。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2023-12-27 DOI: 10.1136/dtb.2023.000057

Overview of:Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med 2023;388:1931-41.

概述：Dequin PF、Meziani F、Quenot JP 等：氢化可的松在重症社区获得性肺炎中的应用。N Engl J Med 2023;388:1931-41.
{"title":"Hydrocortisone for severe community acquired pneumonia in ICU.","authors":"","doi":"10.1136/dtb.2023.000057","DOIUrl":"10.1136/dtb.2023.000057","url":null,"abstract":"<p><p><b>Overview of:</b>Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med 2023;388:1931-41.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50161107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MHRA issues two updates on fluoroquinolone safety MHRA 发布两份氟喹诺酮类药物安全性的最新报告
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2023-12-11 DOI: 10.1136/dtb.2023.000069
BMJ Publishing Group Ltd
### Key learning points The Medicines and Healthcare products Regulatory Agency has issued two updates about serious safety issues associated with systemic fluoroquinolone antibiotics.1 2 In 2019, restrictions on the use of fluoroquinolone antibiotics were introduced because …
#### 学习要点 药品和保健品监管局发布了两份关于全身用氟喹诺酮类抗生素相关严重安全问题的更新1 2。2019 年，对氟喹诺酮类抗生素的使用进行了限制，原因是...
{"title":"MHRA issues two updates on fluoroquinolone safety","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2023.000069","DOIUrl":"https://doi.org/10.1136/dtb.2023.000069","url":null,"abstract":"### Key learning points The Medicines and Healthcare products Regulatory Agency has issued two updates about serious safety issues associated with systemic fluoroquinolone antibiotics.1 2 In 2019, restrictions on the use of fluoroquinolone antibiotics were introduced because …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138573028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bempedoic acid and cardiovascular outcomes. 贝哌酸与心血管结果。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2023-11-29 DOI: 10.1136/dtb.2023.000054

Overview of: Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 2023;388:1353-64.

概述:Nissen SE, Lincoff AM, Brennan D，等。他汀类药物不耐受患者的苯培多酸与心血管预后。中华医学杂志[J]; 2009; 31(2): 357 - 357。
{"title":"Bempedoic acid and cardiovascular outcomes.","authors":"","doi":"10.1136/dtb.2023.000054","DOIUrl":"10.1136/dtb.2023.000054","url":null,"abstract":"<p><p><b>Overview of:</b> Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. <i>N Engl J Med</i> 2023;388:1353-64.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"180"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semaglutide: a new drug for the treatment of obesity. Semagulide：一种治疗肥胖的新药。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2023-11-29 DOI: 10.1136/dtb.2023.000007
Joel Lexchin, Barbara Mintzes

Semaglutide (▼Ozempic solution for injection, ▼Rybelsus tablets-Novo Nordisk) was initially granted market authorisation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In 2021 and 2022, regulatory agencies in the USA and Europe licensed semaglutide (▼Wegovy solution for injection-Novo Nordisk) for the treatment of individuals who are obese, or overweight and who have at least one weight-related comorbidity. Manufacturer-sponsored randomised controlled trials have shown a loss of almost 12% of body weight over a 68-week period, however, once the medication is stopped people regain most of their pretreatment weight. Gastrointestinal adverse events occur commonly with semaglutide, and pancreatitis, diabetic retinopathy and severe allergic reactions have also been reported. Extensive hype in social and general media has resulted in increased demand for semaglutide leading to supply problems across the various licensed products including those used for treatment of diabetes. In the UK, the National Institute for Health and Care Excellence has recommended semaglutide as an option for weight management for a maximum treatment duration of 2 years. Further studies are underway to assess the effect of semaglutide on longer-term health benefits.

Semagrutide(▼注射用Ozenpic溶液，▼Rybelsus片剂Novo Nordisk）最初获得了治疗2型糖尿病的市场授权，作为饮食和运动的辅助药物。2021年和2022年，美国和欧洲的监管机构对赛马鲁肽进行了许可(▼Wegovy注射液Novo Nordisk）用于治疗肥胖或超重且至少有一种与体重相关的合并症的个体。制造商赞助的随机对照试验显示，在68周的时间里，体重减轻了近12%，然而，一旦停止服药，人们就会恢复到治疗前的大部分体重。西格鲁肽常见胃肠道不良事件，胰腺炎、糖尿病视网膜病变和严重过敏反应也有报道。社交媒体和一般媒体上的广泛炒作导致了对赛马鲁肽的需求增加，导致各种许可产品的供应问题，包括用于治疗糖尿病的产品。在英国，国家健康与护理卓越研究所建议将赛马鲁肽作为体重管理的一种选择，最长治疗时间为2年。进一步的研究正在进行中，以评估赛马鲁肽对长期健康益处的影响。
{"title":"Semaglutide: a new drug for the treatment of obesity.","authors":"Joel Lexchin, Barbara Mintzes","doi":"10.1136/dtb.2023.000007","DOIUrl":"10.1136/dtb.2023.000007","url":null,"abstract":"<p><p>Semaglutide (▼Ozempic solution for injection, ▼Rybelsus tablets-Novo Nordisk) was initially granted market authorisation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In 2021 and 2022, regulatory agencies in the USA and Europe licensed semaglutide (▼Wegovy solution for injection-Novo Nordisk) for the treatment of individuals who are obese, or overweight and who have at least one weight-related comorbidity. Manufacturer-sponsored randomised controlled trials have shown a loss of almost 12% of body weight over a 68-week period, however, once the medication is stopped people regain most of their pretreatment weight. Gastrointestinal adverse events occur commonly with semaglutide, and pancreatitis, diabetic retinopathy and severe allergic reactions have also been reported. Extensive hype in social and general media has resulted in increased demand for semaglutide leading to supply problems across the various licensed products including those used for treatment of diabetes. In the UK, the National Institute for Health and Care Excellence has recommended semaglutide as an option for weight management for a maximum treatment duration of 2 years. Further studies are underway to assess the effect of semaglutide on longer-term health benefits.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"182-188"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50161108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differentiation of hydrochlorothiazide-induced dermatitis from stasis dermatitis. 氢氯噻嗪性皮炎与瘀血性皮炎的鉴别。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2023-11-29 DOI: 10.1136/dtb.2023.249884rep
Rewan Abdelwahab, Eric G Tangalos, John Matulis
Summary A woman in her 60s with a history of hypertension and stasis dermatitis presented to a primary care clinic with a bilateral, erythematous rash on the legs, stomach
{"title":"Differentiation of hydrochlorothiazide-induced dermatitis from stasis dermatitis.","authors":"Rewan Abdelwahab, Eric G Tangalos, John Matulis","doi":"10.1136/dtb.2023.249884rep","DOIUrl":"10.1136/dtb.2023.249884rep","url":null,"abstract":"Summary A woman in her 60s with a history of hypertension and stasis dermatitis presented to a primary care clinic with a bilateral, erythematous rash on the legs, stomach","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"189-191"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9746335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A deprescribing intervention from hospital to postacute community care. 从医院到急性期后社区护理的一种描述性干预。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2023-11-29 DOI: 10.1136/dtb.2023.000061

Overview of: Vasilevskis EE, Shah AS, Hollingsworth EK, et al. deprescribing medications among older adults from end of hospitalization through postacute care: a Shed-MEDS randomized clinical trial. JAMA Intern Med 2023;183:223-31.

综述：Vasilevskis EE，Shah AS，Hollingsworth EK等。从住院结束到急性后护理的老年人药物描述：一项Shed-MEDS随机临床试验。《美国医学会杂志》实习医学2023；183:223-31。
{"title":"A deprescribing intervention from hospital to postacute community care.","authors":"","doi":"10.1136/dtb.2023.000061","DOIUrl":"10.1136/dtb.2023.000061","url":null,"abstract":"<p><p><b>Overview of:</b> Vasilevskis EE, Shah AS, Hollingsworth EK, et al. deprescribing medications among older adults from end of hospitalization through postacute care: a Shed-MEDS randomized clinical trial. <i>JAMA Intern Med</i> 2023;183:223-31.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"181"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66783718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changing the complexity of therapeutic monitoring. 改变治疗监测的复杂性。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2023-11-29 DOI: 10.1136/dtb.2023.000049
James A Cave
{"title":"Changing the complexity of therapeutic monitoring.","authors":"James A Cave","doi":"10.1136/dtb.2023.000049","DOIUrl":"10.1136/dtb.2023.000049","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"61 12","pages":"178"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety update: methotrexate and photosensitivity reactions. 安全性更新：甲氨蝶呤和光敏反应。
Q4 Medicine
Drug and Therapeutics Bulletin
Pub Date : 2023-11-29 DOI: 10.1136/dtb.2023.000056

Overview of: Medicines and Healthcare products Regulatory Agency. Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions. Drug Safety Update 2023;17:2.

概述:药品和保健产品监管机构。甲氨蝶呤:建议患者在阳光下注意，避免光敏反应。药物安全更新2023;17:2。
{"title":"Safety update: methotrexate and photosensitivity reactions.","authors":"","doi":"10.1136/dtb.2023.000056","DOIUrl":"10.1136/dtb.2023.000056","url":null,"abstract":"<p><p><b>Overview of:</b> Medicines and Healthcare products Regulatory Agency. Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions. <i>Drug Safety Update</i> 2023;17:2.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"179"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41233269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Drug and Therapeutics Bulletin
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1